|
|
|
| Effect of Lanqin Oral Liquid combined with Ribavirin Aerosol on the recovery time of symptoms and the rate of virus negativity in children with hand,foot and mouth disease |
| LIU Feng CAI Bo LI Baodong WANG Ke |
| Department of Infectious Diseases,the Second People's Hospital of Liaocheng,Shandong Province,Liaocheng 252600,China |
|
|
|
|
Abstract Objective To explore the effect of Lanqin Oral Liquid combined with Ribavirin Aerosol on the recovery time of symptoms and the rate of virus seroconversion in children with hand,foot and mouth disease.Methods A total of 96 children with hand,foot,and mouth disease admitted to the Second People's Hospital of Liaocheng from July 2020 to June 2023 were selected as the study objects and they were divided into a control group(48 cases)and observation group(48 cases)according to random number table method.The control group was treated with Ribavirin Aerosol,while the observation group was treated with Lanqin Oral Liquid on the basis of the control group.Both groups were treated for 2 weeks.The clinical efficacy,symptom recovery time,serum immunoglobulin levels,and virus seroconversion rate between two groups were compared.Results The total clinical effective rate of the observation group was higher than that of the control group,and the symptom recovery time and hospital stay were shorter than those of the control group,and after treatment,the levels of immunoglobulin M (IgM),immunoglobulin G (IgG),and immunoglobulin A (IgA)in the observation group were higher than those in the control group,and the conversion rates of enterovirus and human enterovirus 71 (EV71)virus in the observation group were higher than those in the control group,and the differences were statistically significant（P＜0.05）.Conclusion Treatment with Lanqin Oral Liquid on the basis of Lufovirin Aerosol can significantly enhance clinical efficacy,quickly alleviate clinical symptoms,improve immunoglobulin levels,and increase the rate of virus seroconversion.
|
|
|
|
|
|
| [1] |
王佳，张龙，张晶，等.小儿化毒胶囊联合利巴韦林治疗儿童EV71 感染手足口病的临床效果[J].中华医院感染学杂志，2021，31（10）：1486-1491.
|
| [2] |
陈占锋，张娟.热毒宁注射液联合重组人干扰素α1b 治疗小儿手足口病的临床研究[J].现代药物与临床，2022，37（1）：137-141.
|
| [3] |
孙子发，高健，陈必全.热毒宁注射液联合干扰素雾化吸入治疗手足口病的效果和安全性分析[J].中国医药，2021，16（5）：745-748.
|
| [4] |
杨艳丽，张召，袁莹莹，等.2017-2020 年西安市新城区0～5 岁儿童肠道病毒71 型灭活疫苗接种率分析[J].中国医药科学，2022，12（12）：112-115，146.
|
| [5] |
夏旺存.清热解毒汤联合利巴韦林气雾剂治疗小儿手足口病的疗效及安全性观察[J].四川中医，2021，39（9）：163-165.
|
| [6] |
林爱弟，蓝陈福，李司鹏.金莲花颗粒联合利巴韦林治疗小儿手足口病的临床疗效及对炎症细胞因子的影响[J].中国妇幼保健，2021，36（11）：2556-2559.
|
| [7] |
储开东，季凤华.奥司他韦颗粒联合蓝芩口服液治疗小儿早期甲型流感疗效观察[J].儿科药学杂志，2021，27（4）：34-37.
|
| [8] |
中华人民共和国国家卫生和计划生育委员会.手足口病诊断（2018 年版）[J].中华临床感染病杂志，2018，11（2）：81-82.
|
| [9] |
李利寻，王志飞，谢雁鸣，等.喜炎平注射液治疗手足口病临床应用特征分析研究[J].中草药，2021，52（15）：4641-4648.
|
| [10] |
宋明媚，孙志伟，陆佳赟.不同剂量重组人干扰素治疗对重症手足口病患儿中枢神经系统保护作用[J].中国医药导报，2022，19（3）：95-98.
|
| [11] |
李娜，宋凌，赫金凤，等.清热败毒汤联合利巴韦林治疗小儿手足口病临床研究[J].中华中医药学刊，2020，38（8）：225-228.
|
| [12] |
柳娜娜，陈倩，常甄真，等.利巴韦林喷雾剂联合小儿豉翘清热颗粒对手足口病患儿外周血T 淋巴细胞亚群，血清免疫球蛋白指标和炎性因子的影响[J].现代生物医学进展，2023，23（6）：1151-1195.
|
| [13] |
于梦琦，张婉乔，王成祥，等.基于Meta 分析的热毒宁注射液联合利巴韦林治疗小儿手足口病有效性和安全性评价[J].药物流行病学杂志，2020，29（2）：97-104.
|
| [14] |
董娜，康永平.匹多莫德联合利巴韦林治疗对手足口病患儿疗效及对D-二聚体含量的影响[J].血栓与止血学，2022，28（4）：663-664.
|
| [15] |
向淑芳，薛勇.自拟清解透表方联合利巴韦林治疗小儿手足口病的疗效及对T 淋巴细胞和血清sICAM-1、hs-CRP 水平的影响[J].四川中医，2021，39（9）：160-163.
|
| [16] |
黄欢娣.重组人干扰素α1b 联合利巴韦林对重症手足口病患儿症状改善及血清细胞因子水平的影响[J].中国药物与临床，2021，25（23）：3869-3871.
|
| [17] |
邢美云，张丽娜.热毒宁注射剂结合利巴韦林气雾剂治疗手足口病患儿的临床研究[J].中华养生保健，2021，39（15）：180-181.
|
| [18] |
刘光慧.注射用单磷酸阿糖腺苷联合蓝芩口服液治疗手足口病患儿的效果[J].医疗装备，2020，33（12）：70-72.
|
| [19] |
黄智顺，杨大练，谭敏斯，等.蓝芩口服液联合硫酸镁早期干预对儿童手足口病患儿疗效及对血清免疫球蛋白、CRP 水平的影响[J].中国处方药，2021，19（5）：69-71.
|
| [20] |
陈玲，赵文静，孙艳，等.蓝芩口服液配合干扰素α1b 注射液对疱疹性咽峡炎患儿炎性因子及体液免疫水平的影响[J].海南医学，2021，32（23）：3082-3085.
|
| [21] |
杨艳娜，李文豪，赵惠娅.喜炎平注射液联合蓝芩口服液治疗手足口病的疗效及对免疫功能的影响[J].数理医药学杂志，2021，34（6）：884-886.
|
|
|
|
